Prevention of Aggregation with Albumin

Two critical characteristics for the complete reduction of biotherapeutics aggregation are present in Recombumin® recombinant human albumin (rAlb).

Firstly, it binds promiscuously by using ionic and hydrophobic interactions, shielding otherwise uncovered surfaces that are possible candidates for aggregation.

Secondly, as Recombumin® is evenly distributed throughout the solution, the material creates an insulating environment that reduces undesirable protein to protein interactions.

The two characteristics have been detailed below in the context of a reduction of aggregation of the peptide insulin, as seen by Micro Flow Imaging (MFI) after a number of freeze thaw (FT) cycles.

 

About Albumedix Ltd.Albumedix Ltd.

Too many people battle with diseases that keep them from living a full life. Healthcare professionals work hard every day to provide these people with better therapies. Together with partners, Albumedix utilize its albumin-based drug enhancing products and technologies to enable the development of more effective treatments.

With more than 30 years of experience, we are proud to be recognized as the world leader in recombinant human albumin products and technologies.

As the highest quality recombinant human albumin products ever developed, Albumedix enables the effective formulation of otherwise hard-to-stabilize drugs, cell therapies, and vaccines.

Our albumin-based technologies offer new ways of optimizing drug dosing and enhancing therapeutic performance by increasing the half-life, payload capacity, and tissue specific delivery of active pharmaceutical agents. This results in simpler treatment regimens, better performance, and, ultimately, improved patient outcomes.

Albumedix is headquartered in Nottingham, UK, with both research and large-scale manufacturing facilities. We are all committed to improving patient quality of life and are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 12, 2020 at 3:02 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Albumedix Ltd.. (2020, February 12). Prevention of Aggregation with Albumin. News-Medical. Retrieved on June 07, 2020 from https://www.news-medical.net/whitepaper/20200210/Prevention-of-Aggregation-with-Albumin.aspx.

  • MLA

    Albumedix Ltd.. "Prevention of Aggregation with Albumin". News-Medical. 07 June 2020. <https://www.news-medical.net/whitepaper/20200210/Prevention-of-Aggregation-with-Albumin.aspx>.

  • Chicago

    Albumedix Ltd.. "Prevention of Aggregation with Albumin". News-Medical. https://www.news-medical.net/whitepaper/20200210/Prevention-of-Aggregation-with-Albumin.aspx. (accessed June 07, 2020).

  • Harvard

    Albumedix Ltd.. 2020. Prevention of Aggregation with Albumin. News-Medical, viewed 07 June 2020, https://www.news-medical.net/whitepaper/20200210/Prevention-of-Aggregation-with-Albumin.aspx.

Other White Papers by this Supplier